FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080901368> ?p ?o ?g. }

• W3080901368 endingPage "408" @default.
• W3080901368 startingPage "406" @default.
• W3080901368 abstract "Juvenile dermatomyositis (JDM) is a systemic vasculopathy with weakness and rash, frequently exhibiting a chronic/polycyclic course, and treated with broad immunosuppression. An interferon (IFN) signature correlates with disease activity.1 Interferonopathies have been successfully targeted by janus kinase (JAK) inhibitors.2 3 We report the first comprehensive prospective evaluation of JAK inhibition (baricitinib) in JDM.Four patients (5.8–20.7 years old), with chronically active JDM (≥3/6 core set measures)4 who had failed three to six immunomodulatory medications, were enroled on compassionate use study NCT01724580 (online supplementary methods, online supplementary table 1). Biologics other than intravenous immunoglobulin were washed out and other medications continued.### Supplementary data[annrheumdis-2020-218690supp001.pdf]Subjects were assessed before and 4, 8, 12 and 24 weeks after starting baricitinib (4–8 mg/day divided two times per day) dosed by weight and renal function.3 Significant improvement was noted by week 4 in Physician Global Activity, Patient/Parent Global Activity, and Extramuscular Global Activity, and Cutaneous Dermatomyositis Disease Area and Severity Index (figure 1, online supplementary table 2). Two patients with baseline weakness improved by week 4 (ACR/EULAR Myositis Response Criteria) and showed clinically relevant improvement in Manual Muscle Testing-8 by week 8, confirmed by blinded MRI assessment (online supplementary figures 1 and 2). There was no significant change in muscle enzymes (online supplementary table 3), though some had variable elevations with stable/improved strength. Daily corticosteroids were decreased (0.28 to 0.18 mg/kg/day); other immunosuppressive medications were decreased/discontinued (online supplementary table 1). There were no flares/worsening requiring increased immunosuppression. There was no notable change in calcinosis (n=2).Figure 1 Change in disease activity and pharmacodynamic markers on baricitinib treatment. (A–D) Multiple clinical assessments are shown at …" @default.
• W3080901368 created "2020-09-01" @default.
• W3080901368 creator A5000349051 @default.
• W3080901368 creator A5000777087 @default.
• W3080901368 creator A5002704860 @default.
• W3080901368 creator A5012202221 @default.
• W3080901368 creator A5012901420 @default.
• W3080901368 creator A5021090461 @default.
• W3080901368 creator A5021831388 @default.
• W3080901368 creator A5030955894 @default.
• W3080901368 creator A5032490645 @default.
• W3080901368 creator A5033939944 @default.
• W3080901368 creator A5040260909 @default.
• W3080901368 creator A5040273759 @default.
• W3080901368 creator A5042465946 @default.
• W3080901368 creator A5042947456 @default.
• W3080901368 creator A5048786022 @default.
• W3080901368 creator A5051565540 @default.
• W3080901368 creator A5067851973 @default.
• W3080901368 creator A5071090223 @default.
• W3080901368 creator A5076457631 @default.
• W3080901368 creator A5079918193 @default.
• W3080901368 creator A5080115379 @default.
• W3080901368 creator A5081701569 @default.
• W3080901368 creator A5081756685 @default.
• W3080901368 creator A5091733865 @default.
• W3080901368 date "2020-08-25" @default.
• W3080901368 modified "2023-10-18" @default.
• W3080901368 title "Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis" @default.
• W3080901368 cites W2604745577 @default.
• W3080901368 cites W2769096731 @default.
• W3080901368 cites W2796581040 @default.
• W3080901368 cites W2800751803 @default.
• W3080901368 cites W2890221919 @default.
• W3080901368 cites W2903923806 @default.
• W3080901368 doi "https://doi.org/10.1136/annrheumdis-2020-218690" @default.
• W3080901368 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7904969" @default.
• W3080901368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32843325" @default.
• W3080901368 hasPublicationYear "2020" @default.
• W3080901368 type Work @default.
• W3080901368 sameAs 3080901368 @default.
• W3080901368 citedByCount "44" @default.
• W3080901368 countsByYear W30809013682021 @default.
• W3080901368 countsByYear W30809013682022 @default.
• W3080901368 countsByYear W30809013682023 @default.
• W3080901368 crossrefType "journal-article" @default.
• W3080901368 hasAuthorship W3080901368A5000349051 @default.
• W3080901368 hasAuthorship W3080901368A5000777087 @default.
• W3080901368 hasAuthorship W3080901368A5002704860 @default.
• W3080901368 hasAuthorship W3080901368A5012202221 @default.
• W3080901368 hasAuthorship W3080901368A5012901420 @default.
• W3080901368 hasAuthorship W3080901368A5021090461 @default.
• W3080901368 hasAuthorship W3080901368A5021831388 @default.
• W3080901368 hasAuthorship W3080901368A5030955894 @default.
• W3080901368 hasAuthorship W3080901368A5032490645 @default.
• W3080901368 hasAuthorship W3080901368A5033939944 @default.
• W3080901368 hasAuthorship W3080901368A5040260909 @default.
• W3080901368 hasAuthorship W3080901368A5040273759 @default.
• W3080901368 hasAuthorship W3080901368A5042465946 @default.
• W3080901368 hasAuthorship W3080901368A5042947456 @default.
• W3080901368 hasAuthorship W3080901368A5048786022 @default.
• W3080901368 hasAuthorship W3080901368A5051565540 @default.
• W3080901368 hasAuthorship W3080901368A5067851973 @default.
• W3080901368 hasAuthorship W3080901368A5071090223 @default.
• W3080901368 hasAuthorship W3080901368A5076457631 @default.
• W3080901368 hasAuthorship W3080901368A5079918193 @default.
• W3080901368 hasAuthorship W3080901368A5080115379 @default.
• W3080901368 hasAuthorship W3080901368A5081701569 @default.
• W3080901368 hasAuthorship W3080901368A5081756685 @default.
• W3080901368 hasAuthorship W3080901368A5091733865 @default.
• W3080901368 hasBestOaLocation W30809013682 @default.
• W3080901368 hasConcept C112392421 @default.
• W3080901368 hasConcept C115961737 @default.
• W3080901368 hasConcept C121332964 @default.
• W3080901368 hasConcept C126322002 @default.
• W3080901368 hasConcept C142424586 @default.
• W3080901368 hasConcept C16005928 @default.
• W3080901368 hasConcept C170493617 @default.
• W3080901368 hasConcept C183315844 @default.
• W3080901368 hasConcept C203014093 @default.
• W3080901368 hasConcept C2776090121 @default.
• W3080901368 hasConcept C2778552304 @default.
• W3080901368 hasConcept C2778751314 @default.
• W3080901368 hasConcept C32465701 @default.
• W3080901368 hasConcept C54355233 @default.
• W3080901368 hasConcept C67662055 @default.
• W3080901368 hasConcept C71924100 @default.
• W3080901368 hasConcept C86803240 @default.
• W3080901368 hasConcept C87355193 @default.
• W3080901368 hasConcept C8891405 @default.
• W3080901368 hasConceptScore W3080901368C112392421 @default.
• W3080901368 hasConceptScore W3080901368C115961737 @default.
• W3080901368 hasConceptScore W3080901368C121332964 @default.
• W3080901368 hasConceptScore W3080901368C126322002 @default.
• W3080901368 hasConceptScore W3080901368C142424586 @default.
• W3080901368 hasConceptScore W3080901368C16005928 @default.
• W3080901368 hasConceptScore W3080901368C170493617 @default.
• W3080901368 hasConceptScore W3080901368C183315844 @default.

• next